HK1167829A1 - Co-crystal of etravirine and nicotinamide - Google Patents

Co-crystal of etravirine and nicotinamide

Info

Publication number
HK1167829A1
HK1167829A1 HK12108686.8A HK12108686A HK1167829A1 HK 1167829 A1 HK1167829 A1 HK 1167829A1 HK 12108686 A HK12108686 A HK 12108686A HK 1167829 A1 HK1167829 A1 HK 1167829A1
Authority
HK
Hong Kong
Prior art keywords
etravirine
nicotinamide
crystal
Prior art date
Application number
HK12108686.8A
Other languages
English (en)
Chinese (zh)
Inventor
Matthew F Sansone
Mark Tawa
Julius F Remenar
Lieven Elvire Colette Baert
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of HK1167829A1 publication Critical patent/HK1167829A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12108686.8A 2009-03-30 2012-09-05 Co-crystal of etravirine and nicotinamide HK1167829A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16451609P 2009-03-30 2009-03-30
PCT/EP2010/053970 WO2010112411A1 (en) 2009-03-30 2010-03-26 Co-crystal of etravirine and nicotinamide

Publications (1)

Publication Number Publication Date
HK1167829A1 true HK1167829A1 (en) 2012-12-14

Family

ID=42340730

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12108686.8A HK1167829A1 (en) 2009-03-30 2012-09-05 Co-crystal of etravirine and nicotinamide

Country Status (11)

Country Link
US (1) US8754093B2 (ja)
EP (1) EP2413936B1 (ja)
JP (1) JP5748737B2 (ja)
CN (1) CN102369009B (ja)
AU (1) AU2010230344B9 (ja)
BR (1) BRPI1012666B8 (ja)
CA (1) CA2757228C (ja)
EA (1) EA024299B1 (ja)
ES (1) ES2612485T3 (ja)
HK (1) HK1167829A1 (ja)
WO (1) WO2010112411A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336143B1 (ko) 2011-09-26 2013-12-05 한밭대학교 산학협력단 클로피도그렐의 공결정
ES2637829T3 (es) * 2012-06-15 2017-10-17 Basf Se Cristales multicomponentes que comprenden dasatinib y agentes de formación de cocristales seleccionados
CN103864606A (zh) * 2012-12-17 2014-06-18 中国科学院苏州纳米技术与纳米仿生研究所 二氟尼柳和吡啶甲酰胺类化合物的共晶体及其制备方法
US9896429B2 (en) 2014-05-27 2018-02-20 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
EP3871515A1 (en) 2014-05-27 2021-09-01 R. J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
US10508096B2 (en) 2014-05-27 2019-12-17 R.J. Reynolds Tobacco Company Nicotine salts, co-crystals, and salt co-crystal complexes
WO2016140219A1 (ja) * 2015-03-02 2016-09-09 武田薬品工業株式会社 ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法
DK3379952T3 (da) 2015-11-25 2024-01-08 Reynolds Tobacco Co R Nikotinsalte, co-krystaller og salt-co-krystalkomplekser
WO2019049049A1 (en) 2017-09-05 2019-03-14 R. J. Reynolds Tobacco Company SALTS, CO-CRYSTALS, AND CO-CRYSTAL COMPLEXES OF NICOTINE SALTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11674A (en) 1998-11-10 2005-01-12 Janssen Pharmaceutica Nv HIV Replication inhibiting pyrimidines.
EA005423B1 (ru) 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
JP4906233B2 (ja) * 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
US20070135488A1 (en) 2002-04-13 2007-06-14 Chung You S Amlodipine nicotinate and process for the preparation thereof
US20100041687A1 (en) * 2006-12-06 2010-02-18 Thone Daniel Joseph Christiaan Hydrobromide salt of an anti-hiv compound
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
WO2009011567A1 (en) * 2007-07-16 2009-01-22 Ultimorphix Technologies B.V. Crystalline forms of efavirenz

Also Published As

Publication number Publication date
EA024299B1 (ru) 2016-09-30
US20120028998A1 (en) 2012-02-02
US8754093B2 (en) 2014-06-17
EA201171186A1 (ru) 2012-05-30
CA2757228A1 (en) 2010-10-07
JP5748737B2 (ja) 2015-07-15
AU2010230344B9 (en) 2014-11-27
CN102369009B (zh) 2014-04-30
EP2413936B1 (en) 2016-11-02
JP2012522026A (ja) 2012-09-20
CN102369009A (zh) 2012-03-07
WO2010112411A1 (en) 2010-10-07
BRPI1012666B1 (pt) 2020-12-22
AU2010230344A1 (en) 2011-10-13
ES2612485T3 (es) 2017-05-17
BRPI1012666B8 (pt) 2021-05-25
EP2413936A1 (en) 2012-02-08
CA2757228C (en) 2018-01-02
AU2010230344B2 (en) 2014-07-24
BRPI1012666A2 (pt) 2016-04-05

Similar Documents

Publication Publication Date Title
HK1243417A1 (zh) 吡啶酮和氮雜吡啶酮化合物及使用方法
HK1167829A1 (en) Co-crystal of etravirine and nicotinamide
SG10201405568UA (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
IL214806A0 (en) Prebiotic formulations and methods of use
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
EP2536283A4 (en) PHENYLHETEROARYL DERIVATIVES AND USE METHOD THEREFOR
EP2579831A4 (en) DONATION AND APPLICATION PROCEDURE
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
EP2503887A4 (en) SUBSTITUTED BIARYL DERIVATIVES AND METHODS OF USE
IL265950A (en) Detection and treatment of leprosy
IL257069B (en) Inhibitors of cell death and uses thereof
ZA201301936B (en) Methods and compositions for treatment of diabetes and dyslipidemia
ZA201209666B (en) Salts and polymorhs of dexrabeprazole
EP2394979A4 (en) INTERMEDIATE OF CILASTATIN AND METHOD FOR PREPARING THE SAME
EP2490541A4 (en) 2-SUBSTITUTED ETHYL HYLTHIAZONE DERIVATIVES AND THEIR USE
IL217135A0 (en) Stabilized herbicidal formulations and methods of use
IL224191A (en) Compositions of vitamin d and cmc epi-14 analogues
EP2503891A4 (en) PYRIMIDINE ETHER DERIVATIVES AND METHOD OF USE THEREOF
IL219935A0 (en) Small pyrimidine derivatives and methods of use thereof
GB2478317B (en) Herbicidal composition and method of use thereof
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法
EP2404613A4 (en) New uses of fibrinogen-420 and its active domain
HUP0900532D0 (en) Amine-epoxy appucts and use of them